258 related articles for article (PubMed ID: 24504006)
1. Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women.
Roxby AC; Atkinson C; Asbjörnsdóttir K; Farquhar C; Kiarie JN; Drake AL; Wald A; Boeckh M; Richardson B; Emery V; John-Stewart G; Slyker JA
PLoS One; 2014; 9(2):e87855. PubMed ID: 24504006
[TBL] [Abstract][Full Text] [Related]
2. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial.
Drake AL; Roxby AC; Kiarie J; Richardson BA; Wald A; John-Stewart G; Farquhar C
PLoS One; 2012; 7(4):e34635. PubMed ID: 22509337
[TBL] [Abstract][Full Text] [Related]
3. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
Leruez-Ville M; Ghout I; Bussières L; Stirnemann J; Magny JF; Couderc S; Salomon LJ; Guilleminot T; Aegerter P; Benoist G; Winer N; Picone O; Jacquemard F; Ville Y
Am J Obstet Gynecol; 2016 Oct; 215(4):462.e1-462.e10. PubMed ID: 27083761
[TBL] [Abstract][Full Text] [Related]
4. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake AL; Roxby AC; Ongecha-Owuor F; Kiarie J; John-Stewart G; Wald A; Richardson BA; Hitti J; Overbaugh J; Emery S; Farquhar C
J Infect Dis; 2012 Feb; 205(3):366-75. PubMed ID: 22147786
[TBL] [Abstract][Full Text] [Related]
5. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
[TBL] [Abstract][Full Text] [Related]
6. Maternal Highly Active Antiretroviral Therapy Reduces Vertical Cytomegalovirus Transmission But Does Not Reduce Breast Milk Cytomegalovirus Levels.
Slyker JA; Richardson B; Chung MH; Atkinson C; Ásbjörnsdóttir KH; Lehman DA; Boeckh M; Emery V; Kiarie J; John-Stewart G
AIDS Res Hum Retroviruses; 2017 Apr; 33(4):332-338. PubMed ID: 27796131
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
[TBL] [Abstract][Full Text] [Related]
8. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
9. Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection.
Slyker J; Farquhar C; Atkinson C; Ásbjörnsdóttir K; Roxby A; Drake A; Kiarie J; Wald A; Boeckh M; Richardson B; Odem-Davis K; John-Stewart G; Emery V
Clin Infect Dis; 2014 Feb; 58(4):564-72. PubMed ID: 24192386
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.
Cowley NJ; Owen A; Shiels SC; Millar J; Woolley R; Ives N; Osman H; Moss P; Bion JF
JAMA Intern Med; 2017 Jun; 177(6):774-783. PubMed ID: 28437539
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
[TBL] [Abstract][Full Text] [Related]
14. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
15. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
[TBL] [Abstract][Full Text] [Related]
16. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
17. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.
Chanouzas D; Dyall L; Nightingale P; Ferro C; Moss P; Morgan MD; Harper L
Trials; 2016 Jul; 17(1):338. PubMed ID: 27450392
[TBL] [Abstract][Full Text] [Related]
18. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
20. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
